Jun. 17 at 10:56 PM
$VCNX Vaccinex secured a
$60 million financing agreement to initiate an enlarged Phase 2b clinical trial for pepinemab to treat Alzheimer's Disease. While a definitive start date has not been formally scheduled, it is currently in the active planning and preparation phases., thats more than 6 months ago!